Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580340 | 1.00 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL3572587 | 1.00 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL4094667 | 0.95 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL3574322 | 0.93 | HRH3 (0.86) | HRH3ACHERAD52 | |
| SCHEMBL3574289 | 0.93 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL3581031 | 0.93 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL3580727 | 0.92 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL30777699 | 0.92 | HRH3 (1.00) | HRH3ACHERAD52TSHR | |
| SCHEMBL3569242 | 0.91 | HRH3 (1.00) | HRH3ACHERAD52 | |
| SCHEMBL14287716 | 0.91 | HRH3 (0.83) | HRH3ACHERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| CN-119818506-A | Pharmaceutical composition for preventing and/or treating pain and application thereof | 江苏海洋大学 | 2025-04-15 | — | — | CN | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | claimed |
| EP-4251148-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Richter Gedeon Nyrt. (HU) | 2023-10-04 | — | — | EP | claimed |
| WO-2022113008-A1 | HISTAMINE H3 RECEPTOR ANTAGONISTS/INVERSE AGONISTS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | RICHTER GEDEON NYRT. (HU) | 2022-06-02 | — | — | WO | claimed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | claimed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | claimed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | disclosed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | HRH3 2876/4885ACHE 3018/4885RAD52 4709/4885 |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | HNMT, HRH2, HRH3 | HRH3 3/4885ACHE 506/4885RAD52 3855/4885 |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | HRH4, HRH3, HRH2 | HRH3 2/4885ACHE 1411/4885RAD52 3816/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | HRH3 41/4885ACHE 159/4885RAD52 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.